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Prevention of Vitamin K Deficiency Bleeding in Newborn
Infants: A Position Paper by the ESPGHAN Committee
on Nutrition
Walter A. Mihatsch, yChristian Braegger, zJiri Bronsky, §Cristina Campoy, jjMagnus Domello¨f,
Mary Fewtrell, #Natasˇa F. Mis, Iva Hojsak, yyJessie Hulst, zzFlavia Indrio,
§§jjjjAlexandre Lapillonne, ##Christian Mølgaard, Nicholas Embleton,
and yyyzzzJohannes van Goudoever, ESPGHAN Committee on Nutrition
ABSTRACT
Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin
K plasma concentrations is a serious risk for newborn and young infants and
can be largely prevented by adequate vitamin K supplementation. The aim of
this position paper is to define the condition, describe the prevalence, discuss
current prophylaxis practices and outcomes, and to provide recommen-
dations for the prevention of VKDB in healthy term newborns and infants.
All newborn infants should receive vitamin K prophylaxis and the date, dose,
and mode of administration should be documented. Parental refusal of
vitamin K prophylaxis after adequate information is provided should be
recorded especially because of the risk of late VKDB. Healthy newborn
infants should either receive 1 mg of vitamin K1 by intramuscular injection
at birth; or 3 2 mg vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6
weeks; or 2 mg vitamin K1 orally at birth, and a weekly dose of 1 mg orally
for 3 months. Intramuscular application is the preferred route for efficiency
and reliability of administration. The success of an oral policy depends on
compliance with the protocol and this may vary between populations and
healthcare settings. If the infant vomits or regurgitates the formulation
within 1 hour of administration, repeating the oral dose may be appropriate.
The oral route is not appropriate for preterm infants and for newborns who
have cholestasis or impaired intestinal absorption or are too unwell to take
oral vitamin K1, or those whose mothers have taken medications that
interfere with vitamin K metabolism. Parents who receive prenatal education
about the importance of vitamin K prophylaxis may be more likely to
comply with local procedures.
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(JPGN 2016;63: 123–129)
H ealthy newborns and infants are at risk of developing severehemorrhages and especially intracranial hemorrhages due to
physiologically low concentrations of vitamin K that result in low
concentrations of vitamin K–dependent clotting factors. Therefore
prophylaxis against vitamin K deficiency bleeding (VKDB)
is important.
The aim of this position paper is to define the condition,
describe the prevalence, discuss current prophylaxis practices and
outcomes, and to provide recommendations for setting up local
guidelines for the prevention of VKDB in newborns and infants.
HISTORY OF HEMORRHAGIC DISEASE
OF THE NEWBORN
Hemorrhagic disease of the newborn (1) was first system-
atically described by Charles Townsend in 1894 (2). He described
50 cases of a bleeding disorder that occurred in 0.6% of newborn
infants usually on days 2 to 3. This is nowadays classified as the
classic form of VKDB and mainly affects the skin, gastrointestinal
tract, and brain. The case fatality rate was 62%, whereas surviving
infants typically recovered within 5 days. At that time it was,
however, impossible to differentiate sepsis-induced bleeding
disorders such as disseminated intravascular coagulation from
VKDB. The average incidence in unsupplemented populations
has been estimated to be 0.25% to 1.7% (3) based on reported
incidences of 0.25% (4), 0.33% (5) up to 13.9% (6) in a single study
(also including hemorrhages of the circumcision wound).
The underlying pathophysiology was first described by the
biochemist Henrik Dam. In 1929 he discovered a ‘‘Coagulation’’
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factor in chicken (coagulations vitamin, vitamin K) (7). Sub-
sequently, prothrombin deficiency was documented in newborns
with VKDB by Brinkhous et al (8) and Dam et al (9–15). Waddell
et al (16) showed that vitamin K prevents hemorrhagic disease of
the newborn. Vitamin K was first synthesized in 1939 (17) and in
1961 the committee on nutrition of the American Academy of
Pediatrics first recommended postnatal prophylaxis for classic
VKDB using 0.5 to 1.0 mg vitamin K parenterally or 1.0 to 2.0
mg orally (18). It is important to note that the incidence of VKDB in
the USA had already significantly decreased over the years before
this recommendation was published, probably because of the
declining incidence of breastfeeding from 1930 to 1960. Human
milk vitamin K concentration is significantly lower than infant
formula vitamin K concentration and classic VKDB has mostly
been seen in breastfed infants (19,20). The American Academy of
Pediatrics reconfirmed its recommendation in 1993 (21). More
recently, in 2003, intramuscular (IM) prophylaxis only using 0.5
to 1 mg vitamin K1 has been recommended (3).
In 1966, the first reports from Thailand of a new VKDB
syndrome were published that typically presented between 1 and
2 months of life and which is now classified as late VKDB. In 1977
Bhanchet et al (22) who first described this syndrome, summarized
their studies of 93 affected predominantly breastfed (98%) Thai
infants. Their incidence of intracranial bleeding was 63%. More
reports from South East Asia and Australia followed. In infants
without vitamin K prophylaxis the incidence of late VKDB (per
100,000 births) has been estimated to be 4.4 in the United Kingdom,
7.2 in Germany, and as high as 72 in Thailand (23). It is important to
take into consideration that VKDB occurs more frequently in the
Asian population compared to the Caucasian population. This may
be explained by the 6-fold higher incidence of biliary atresia in Asia
compared to Western Europe (24).
In infants born to mothers using anticonvulsant drugs (eg,
phenobarbital, phenytoin, carbamazepine, etc) an increased inci-
dence of early VKDB within the first 24 hours has been observed
(25,26). More recent data critically discussed this association; how-
ever, a causal link cannot be excluded (27). Postnatal IM vitamin K
corrects biochemical abnormalities in these infants within 2 hours
(27). Prenatal maternal vitamin K treatment has been hypothesized to
prevent early VKDB in these infants (28); however, this concept still
warrants further evaluation (29). Therefore, immediate postnatal IM
Vitamin K administration is currently regarded as the optimum
VKDB prophylaxis for this group of infants.
VITAMIN K
Vitamin K is a family of fat-soluble 2-methyl-1,4-naphtho-
quinones with a variable alkyl substituent at the 3 position (19,30).
Vitamin K is required for theg-carboxylation of coagulation factors II
(prothrombin), VII, IX, X, protein C, and protein S. It acts as an
essential cofactor for the conversion of specific peptide-bound
glutamate residues to g-carboxyglutamate residues. The collective
abbreviation for these under-carboxylated molecules is PIVKA
(proteins induced by vitamin K absence), and includes, for example,
PIVKA-II, which is the glutamate precursor of prothrombin (factor
II). There are additional vitamin-K–dependent proteins such as
osteocalcin or matrix GLA protein the function of which is less clear.
Relevant Forms of Vitamin K
(1) Phylloquinone (vitamin K1) is synthesized by plants and algae,
for example, green leafy vegetables such as spinach, brussels
sprouts, cabbage, lettuce, and broccoli. This is the only form
used therapeutically in humans.
(2) Multiple menaquinones (vitamin K2), synthesized by bacteria
such as intestinal bacteria and found in egg yolk, chicken, beef,
liver, fermented products such as cheese, and in fermented
vegetables such as cabbage or natto (fermented soybeans).
(3) The synthetic form menadione (vitamin K3) is no longer used
for oral vitamin K prophylaxis because of potential toxicity.
Hemolytic anemia has been reported in glucose-6-phosphate
dehydrogenase deficient infants treated with vitamin K3.
The intestinal absorption of dietary vitamin K, mainly phyl-
loquinone (vitamin K1), is thought to be governed by the same
principles established for other fat-soluble vitamins, and in healthy
adults the efficiency of absorption is about 80% (19). Phylloquinone
is the major circulating form of vitamin K but in addition there are
small amounts of menaquinones (vitamin K2) (19). Although
phylloquinone in blood must have been derived exclusively from
the diet, it is not known whether circulating menaquinones are
derived from the diet, intestinal flora, or both. Human liver stores
normally compromise about 90% menaquinones and 10% phyllo-
quinone (31). Functionally, menaquinones seem to be less import-
ant because dietary phylloquinone deficiency induces subclinical
signs of vitamin K deficiency without a change of hepatic mena-
quinone stores (32). Hepatic menaquinone stores may not be
available to microsomal y-glutamyl carboxylase (31). There is
no menaquinone detectable in newborns (33–35), and at 1 year
of age hepatic menaquinone stores are still significantly lower than
that in adults (32,34).
Vitamin K does not easily cross the placenta and the average
maternal/fetal concentration gradient is within the range of 20:1 to
40:1 (19). The fetal plasma vitamin K concentration is very low and
consequently at birth concentrations of clotting factors are low.
Increased PIVKA II concentrations (>10 ng/mL) have been found
in the umbilical cord blood in 10% to 50% of healthy term and
preterm infants, which is a biomarker of low vitamin K level
(36,37). At least a transient increase in fetal vitamin K1 concen-
tration has been observed with maternal vitamin K1 supplement-
ation; however, no significant effect on vitamin K–dependent
coagulation factors has been found (19). Therefore prenatal
maternal vitamin K1 supplementation does not prevent VKDB.
CLASSIFICATION OF VITAMIN K DEFICIENCY
BLEEDING IN NEWBORN INFANTS AND
INFANTS
VKDB of the newborn has been classified (19,38) by age of
onset into early (<24 hours), classical (days 1–7) and late (>1 week
<6 months), and by etiology into idiopathic and secondary in 1999
by the Pediatric and Perinatal Subcommittee of the International
Society on Thrombosis and Hemostasis (39). There are few data on
the relative frequencies of early, classic, and late VKDB. A regional
epidemiological study from Malaysia in the 1990s, however,
enables calculation of a lower threshold of the incidences (40).
Within a 2-year period 42 VKDB infants were admitted to a single
regional pediatric hospital likely to provide care for all such infants.
In a population in which most infants were breastfed (96%) and in
which vitamin K prophylaxis was infrequent (83% not supple-
mented) the incidences of early, classic and late VKDB were at least
1/7000, 1/4000, and 1/8000, respectively. The relative proportions
were 6:10:5 (Table 1).
VITAMIN K METABOLISM OF THE NEWBORN
AND RISK FACTORS FOR VKDB
Although plasma vitamin K1 concentration is very low
immediately after birth, adult levels have been recorded on days
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3 to 4 following supplementation (53,54) and levels are higher in
formula-fed infants compared to breastfed infants. Human milk
vitamin K1 concentration (median 2.5 mg/L [0.85–9.2 mg/L]) is
significantly lower than currently available formula milk (4–25 mg/
100 kcal approximately corresponding to 24–175 mg/L) (55,56).
On average daily vitamin K1 intake of breastfed infants is <1 mg
within the first 6 months of life, whereas the intake of formula-fed
infants is on average up to 100 times higher (57). With regard to
global coagulation tests such as prothrombin time (PT) there is no
significant difference between breast- and formula-fed infants
(53,57). PIVKAs are, however, much more commonly reported
in breastfed infants (54,58). Formula vitamin K1 exceeds the
recommended vitamin K intake of at least 5 mg/day (30). Because
breastfeeding fails to provide this intake, and because VKDB
is much more common in unsupplemented breastfed infants it
is recommended that all infants receive some form of
supplementation.
The major risk factor for classic VKDB is a low plasma
vitamin K concentration, due to low levels in breast milk and/or
inadequate vitamin K prophylaxis in newborn infants, all of whom
are vitamin K deficient at birth. The effects are manifest by the
presence of PIVKA and lower levels of vitamin K–dependent
coagulation factors and of other vitamin K–dependent proteins
such as the osteoblast product, osteocalcin. Elevated PIVKA-II
levels (>10 ng/mL) have been found in the umbilical cord blood
of 10% to 50% of healthy preterm or term newborn infants (36,37).
At the age of 4 to 5 days PIVKA have been found in up to 70%
of healthy unsupplemented newborn infants (59). In addition, factor
II and VII activity has been reported to be reduced in infants who
did not achieve a breastfeeding volume of 100 mL/kg at 3 to 4 days
of age (59). Therefore classic VKDB may at least partially be a
consequence of insufficient or delayed establishment of breastfeed-
ing (59). Intramuscular or oral (1.0 mg) vitamin K prophylaxis has
been found to be equally effective in improving biochemical indices
of coagulation status (PIVKA) at 1 to 7 days (60–62).
The major risk factors for late VKDB are low plasma vitamin
K concentrations due to insufficient vitamin K prophylaxis, and
breastfeeding combined with cholestatic liver impairment, which
may be subclinical or transient (63,64).
SAFETY OF VITAMIN K PREPARATIONS
There are no data to determine the upper safe level of vitamin
K in general in infancy. In 1992 Jean Golding et al (65) published
epidemiological data suggesting that certain forms of childhood
cancer were associated with IM vitamin K injections. The
speculated biological mechanism of carcinogenesis (induction of
sister chromatid exchange) did not accord with other information
from the literature about in vivo effects of vitamin K or other tests of
carcinogenicity (21). Most expert opinion currently suggest that a
causal relation between IM injection of vitamin K and childhood
cancer is not plausible (3,23) and the hypothesized association has
never been confirmed in other large epidemiological studies. On the
contrary, due to the lack of large randomized studies, this hypoth-
esis has not been disproved (66,67).
DIAGNOSIS OF VITAMIN K DEFICIENCY
BLEEDING
A confirmed case of VKDB should fulfill the criteria of
having a PT that is 4 times the control value and display at least
one of the following (68):
(1) Normal or raised platelet count, normal fibrinogen, and absent
fibrin degradation products.
(2) PT returning to normal within 30 to 20 minutes after
intravenous vitamin K administration (69,70). In general
there is no need for supplementation of coagulation factors
(41).
(3) PIVKA (usually that of factor II) level exceeding normal
controls (41).
PROPHYLAXIS FOR VITAMIN K DEFICIENCY
BLEEDING
Intramuscular Injection of Vitamin K
In 1961 and 1993 the American Academy of Pediatrics
recommended early postnatal vitamin K prophylaxis using 0.5 to
1.0 mg vitamin K parenteral or 1.0 to 2.0 mg orally (18,21). In 2003
the IM injection of 1 mg vitamin K at birth was proposed as standard
of care of healthy newborn infants (3). The argument in favor of IM
prophylaxis was that a single injection was more reliably adminis-
tered, and likely to result in a depot supply over the ensuing weeks
of risk. Therefore this policy is widely used worldwide. Epidemio-
logical surveillance data have shown that this policy virtually
prevents classic and late VKDB (incidence <0.2/100.000)
(23,68,71,72). Despite the use of postnatal 1 mg IM injection there
are still some rare cases of late VKDB, which warrant further
evaluation (41,73–75). Adverse effects of IM vitamin K injections
such as local infections have never been systematically assessed;
however, it is likely to be painful for newborn infants.
TABLE 1. Classification of vitamin K deficiency bleeding of the newborn infant (41)
Syndrome Time of presentation Common bleeding sites (28,38,42) Comments
Early VKDB 0–24 h Subperiosteal hemorrhage of the skull
(cephalohematoma), intracranial, brain,
intrathoracic, intra-abdominal, umbilical stump
Maternal drugs are a frequent cause (eg, coumarin-
anticoagulants such as warfarin, enzyme-inducing
drugs, eg, anticonvulsants, and some
tuberculostatic drugs) (28,43–46)
Classic VKDB 2–7 days (2) Gastrointestinal tract, skin, adrenal gland, nose,
wound from circumcision, intracranial, umbilical
stump
Mainly idiopathic, maternal drugs (18,42,47,48)
Late VKDB 2–12 wk (23,49–52) Intracranial, skin, gastrointestinal Most commonly presenting feature of underlying
disease resulting in reduced vitamin K absorption
(eg, cystic fibrosis, biliary atresia, or other liver
diseases with cholestasis), occasionally idiopathic
VKDB ¼ vitamin K deficiency bleeding.
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Oral Supplementation of Vitamin K
Worldwide, oral supplementation became more widespread
after the article by Golding et al in 1992 (65) and is still used despite
the association between IM vitamin K and childhood cancer never
being reconfirmed (66,67).
Oral vitamin K prophylaxis policies vary in terms of dose and
frequency, and appear to offer virtually complete protection from
early and classic bleeding. The associated incidence of late VKDB
has, however, repeatedly been observed to be higher when com-
pared to a single 1 mg IM dose at birth (23,68,76,77).
In order to prevent late VKDB in addition to early and classic
bleeding in Europe 3 oral prophylaxis patterns have been developed
and evaluated. Because there are no randomized head-to-head
comparison trials, and such trials will probably never be conducted,
efficiency of individual policies can only be assessed by surveil-
lance data. These data are always at risk of underreporting (78).
In Germany using a 3 2 mg oral vitamin K1 prophylaxis
policy an incidence of late VKDB of 0.44/100,000 (95% CI 0.19–
0.87) has been reported (79). Taking an underreporting bias of 57%
(38%–76%) (78) into account the estimated incidence was 0.73/
100,000 (95% CI 0.23–2.2). In Switzerland in 458,184 newborn
infants in 2005 to 2011 one early (18 hours of age) and 4 late VKDB
cases were observed (80). All infants were breastfed and in all but
one of the infants the parents declined vitamin K prophylaxis. In the
remaining infant only the first 2 oral vitamin K doses had been
given. All infants with late VKDB had some cholestatic liver
disease. Therefore, in infants with complete VKDB prophylaxis
(oral 3 2 mg) there was a combined risk for classic and late VKDB
of 0/100,000 (95% CI 0–0.81) (80). The degree of underreporting in
the Swiss study is, however, unknown. At 24 weeks of age an
additional fully breastfed infant developed very late VKDB, in the
absence of cholestatic liver disease. Of note these published effi-
cacy data depended on administration of oral vitamin K by health-
care professionals (Table 2).
Taking these data together, there is some evidence that the
oral 3 2 mg policy may be less effective than a single postnatal 1
mg IM injection (73,79). In all infants with late VKDB, there was a
combination of previously unknown cholestatic liver disease
together with breastfeeding. In infants with conjugated hyperbilir-
ubinemia intestinal absorption of oral vitamin K prophylaxis is
unreliable (90).
In contrast to promising early data (68,91) on the previous
Dutch oral policy (1 mg after birth followed by 25 mg/day for weeks
2–13) later extensive surveillance data suggested that this policy
was associated with the highest incidence of late VKDB of all the
policies listed in the table above (85). Concerning the cause of the 6
reported cases of late VKDB there was 1 case of idiopathic VKDB,
1 case in association with breast milk jaundice, and 4 cases of
previously unrecognized cholestasis because of biliary atresia. In
the Netherlands annually approximately 5 infants experienced
serious hemorrhage. After evaluation of current literature and
advice from The Health Council of the Netherlands, vitamin K
dosage was adapted for all breastfed infants from day 8 to 3 months
(12th week of life) following birth by raising the daily dose from
25 to 150 mg/day (84). This policy, however, still warrants
epidemiological evaluation.
In Denmark, no cases of VKDB were reported during a
period when the following policy was used: 2 mg oral at birth and
1 mg weekly orally administered vitamin K during the first 3 months
of life. This was given to at least 400,000 infants during a 9-year
surveillance period (88,89). Importantly, in infants with previously
unknown biliary atresia this regimen seemed to be as effective as
the single postnatal 1 mg IM injection (92). Weekly oral admin-
istration of 1 mg requires a higher degree of parental compliance
than an oral policy of 3 2 mg vitamin K1 postnatal, on day 3 to 10,
and at 4 to 6 weeks. In 2000 in Denmark the National Board of
Health (Sundhedsstyrelsen) evaluated the literature and concluded
that IM prophylaxis gave better protection against VKDB, along-
side a recognition that IM injection had no apparent relation with
TABLE 2. Recent surveillance data of vitamin K deficiency bleeding prophylaxis policies (efficacy is given ATP)
VKDB prophylaxis policy Country
Evaluated in
N infants Associated classic/late VKDB incidence per 100,000
Oral prophylaxis 3 2 mg
3 2 mg oral (postnatally, days 3–10 and weeks
4–6)
Germany 1,817,769 0.44 (95% CI 0.19–0.87) (79); taking underreporting
(78) into account the estimated incidence may be 0.73
(95% CI 0.23–2.2) 76
Switzerland 458,184 0.0 (95% CI 0.0–0.81) (80)
Total 2,275,953 8 Cases
0.35 (95% CI 0.16–0.69) (79,80)
1 mg IM prophylaxis
1 mg IM postnatally New Zealand 654,000 0.16 (95% CI 0–0.46) (72)
No uniform policy (73,81–83) most commonly 1
mg IM postnatally but several regions use oral
UK 1,700,000 0.24 (0.0–0.35) (73)
Total 2,354,000 5 cases
0.21 (95% CI 0.06–0.5) (72,73)
Policies no longer in reported use
1 mg oral postnatally; 25 mg/day oral days 8–90 The
Netherlands
(until 2011)
(84)
187,910 3.2 (95% CI 1.2–6.9) (85)
2 mg oral postnatally; 1 mg/wk oral for 3 mo Denmark
(until 2000)
(86,87)
400,000 0.0 (95% CI 0.0–0.9) (88,89)
CI ¼ confidence interval; VKDB ¼ vitamin K deficiency bleeding.
Mihatsch et al JPGN  Volume 63, Number 1, July 2016
126 www.jpgn.org
 Copyright © ESPGHAL and NASPGHAN. All rights reserved.
the risk of cancer. Therefore, postnatal 1 mg IM vitamin K
prophylaxis was recommended as the standard of care (86). In
addition at this time it was no longer possible to obtain the oral
preparation of vitamin K because of technical problems (73). This
recommendation was reconfirmed in 2010 (87).
In Great Britain in 2006 routine vitamin K prophylaxis was
recommended by the National Institute for Clinical Excellence
(NICE) to be administered as a single dose of 1 mg IM as this is
the most efficacious and cost-effective method of administration
(83). Alternatively (second line), 2 doses of 2 mg oral vitamin K
should be given at birth and at 4 to 7 days and a third dose in
exclusively breastfed infants only at 1 month. As a third alternative,
the Danish regimen may be used (81,82).
Finally it is important to consider that although there are no
randomized head-to-head comparison trials comparing different
policies, these are unlikely given the low incidence of VKDB in
supplemented infants.
VITAMIN K PREPARATIONS
The available data do not permit the recommendation of one
specific vitamin K preparation. Pharmacokinetic studies of a mixed
micellar vitamin K preparation suggested a higher oral bioavail-
ability compared with a normal vitamin K preparation (93). This
theoretical advantage of the pediatric mixed micellar preparation of
vitamin K has never been demonstrated in randomized controlled
trials (76). Of note, the data suggesting better oral bioavailability
were based on only 3 children experiencing cholestasis (93). In
Germany surveillance of late VKDB observed no significant benefit
of the mixed micellar vitamin K preparation (RR 0.58; 95% CI
0.23–1.47). Because of the low incidence of late VKDB (18 infants)
the sample size of 3.2 million children was, however, insufficient to
detect a significant difference (79).
In contrast to IM injections, an oral vitamin K policy may be
easier to achieve, and may also be more acceptable to some parents
and healthcare providers. Unpredictable absorption, unclear com-
pliance with repeated dosing, insufficient parental health access (eg,
minorities, asylum seeker, and refugees), and incomplete appli-
cation (eg, posseting or vomiting that requires repeat adminis-
tration) remain important disadvantages. A variety of different
products are used; however, caution must be taken, because a
number of these may not have undergone pharmaceutical
quality control.
The pharmacokinetics of intravenous (IV) vitamin K are not
very well known, but it is likely similar to that of vitamin K given
orally. IV administration does not seem to bring the same efficiency
as the IM route for the prevention of the late form of VKDB
especially if the injection is not repeated (73). The slower increase
in urinary excretion of vitamin K metabolites after IM injection
compared with an equivalent dose given by the IV route gives
support to a depot effect whereby lipophilic vitamin K1 leaches out
slowly from the muscular site of injection into the circulation. In
contrast the rapid increase in urinary excretion of vitamin K
metabolites after IV injection suggest a more rapid but transient
effect of the IV injection (94). IV vitamin K1 administration may be
considered in preterm infants, sick term infants, or infants with
cholestatic liver disease. The use of IV vitamin K1 has, however, not
been extensively examined for prophylaxis of VKDB.
CONCLUSIONS
(1) VKDB due to physiologically low vitamin K plasma
concentrations is a serious risk for newborn and young infants.
(2) Adequate vitamin K supplementation prevents the vast
majority of VKDB.
(3) Intramuscular application is the preferred route for efficiency
and reliability of administration.
Data from some countries suggest IM application may be
more effective than 3 2 mg oral prophylaxis for prevention of late
VKDB (68,71,79,95). Analysis of the more recent epidemiological
data obtained from>4.5 million children (Table 2) does not suggest
a significant difference between these 2 options with regard to the
efficacy in prevention of late VKDB.
RECOMMENDATIONS
(1) All newborn infants should receive vitamin K prophylaxis.
(2) Vitamin K prophylaxis and the mode of administration should
be documented.
(3) Parental refusal of vitamin K prophylaxis after adequate
information is provided should be documented especially
because of the risk of late VKDB (96,97).
(4) Healthy newborn infants should either receive:
(a) 1 mg of Vitamin K1 by IM injection at birth,
or
(b) 3 2 mg Vitamin K1 orally at birth, at 4 to 6 days and at 4
to 6 weeks.
or
(c) 2 mgVitamin K1 orally at birth, and aweekly dose of 1mg
orally for 3 months.
(5) The success of an oral policy depends on compliance with the
protocol and this may vary between populations and healthcare
settings. If the infant vomits or regurgitates the formulation
within 1 hour of administration, repeating the oral dose may
be appropriate.
(6) The oral route is not appropriate for preterm infants and for
newborns who are unwell, have cholestasis or impaired
intestinal absorption or are unable to take oral vitamin K, or
those whose mothers have taken medications that interfere
with vitamin K metabolism.
General Advice
(1) Healthcare providers must develop local policies, procedures,
and guidelines for the administration of prophylactic vitamin
K to infants, and conduct regular audit to ensure compliance
and efficacy. The date, dose, and route of administration must
be recorded in the infant’s personal health record (expert
opinion of the committee).
(2) Parents who receive information during the antenatal period
about the importance of vitamin K prophylaxis may be more
likely to comply with local procedures (98).
FUTURE RESEARCH TOPICS
(1) Robust national surveillance data of VKDB, which require
accurate documentation of policies and procedures.
(2) Efficacy and quality control of individual vitamin K products
used for supplementation.
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